Arthritis of large joints shown as a rare clinical feature of cytokine release syndrome after chimeric antigen receptor T cell therapy A case report

被引:8
作者
Wang, Li-Xin [1 ]
Chen, Xiaoping [1 ]
Jia, Mingming [2 ]
Wang, Shengdian [2 ]
Shen, Jianliang [1 ]
机构
[1] Navy Gen Hosp PLA, Dept Hematol, Beijing 100048, Peoples R China
[2] Chinese Acad Sci, Inst Biophys, Key Lab Infect & Immun, Beijing, Peoples R China
关键词
arthritis; chimeric antigen receptor (CAR)-T cell therapy; cytokine release syndrome;
D O I
10.1097/MD.0000000000010455
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rationale: Chimeric antigen receptor (CAR)-T cell therapy is a novel type of therapy that is being used in an increasing number of patients with acute lymphoblastic leukemia (ALL). Cytokine release syndrome (CRS) is the most common complication following CAR-T treatment, but the current understanding of the clinical manifestations and pathogenesis of CRS is still limited. Patient concerns: A 34-year-old male patient was diagnosed with ALL in June 2015. Complete remission (CR) was achieved after induction chemotherapy. The patient received 8 cycles of consolidation chemotherapy to maintain CR. In May 2017, the patient had recurrent ALL. Induction chemotherapy was given again, but without remission. In October 2017, CAR-T cell therapy was given. On October 14, the patient was pretreated with an FC regimen (fludarabine phosphate 50 mg qd on days 1-3; cyclophosphamide 0.4 g qd on days 1-3). CAR-T cells were infused on October 19 and October 20, with the number of infused cells at 2 x 10(5)/kg and 1 x 10(5)/kg, respectively. On October 25, the patient had a high fever, swelling, and pain in the large joints of the limbs, and joint effusion. Diagnosis: This patient was diagnosed with relapsed ALL, and he developed CRS after CAR-T therapy. Interventions: Tacilizumab (400 mg) was infused after CRS was diagnosed, and another dose of tacilizumab (240 mg) was given 6 days later. The pain was also treated with an analgesic drug. Methylprednisolone (1 mg/kg) was given to treat arthritis of the large joints. Outcomes: The patient's temperature was back to normal within 1 hour following the treatment of tacilizumab, but the pain in the large joints was progressively aggravated. The joint swelling and pain were obviously alleviated after the treatment of methylprednisolone, and the joint mobility was gradually recovered. Lessons: CRS after CAR-T therapy can manifest as a high fever with swelling and pain in the large joints of the limbs, similar to rheumatoid arthritis. Tocilizumab can lower the body temperature, but it has no significant effect on arthritis. Glucocorticoids can rapidly alleviate joint swelling and pain.
引用
收藏
页数:4
相关论文
共 50 条
  • [41] Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies
    Kampouri, Eleftheria
    Little, Jessica S.
    Rejeski, Kai
    Manuel, Oriol
    Hammond, Sarah P.
    Hill, Joshua A.
    TRANSPLANT INFECTIOUS DISEASE, 2023, 25
  • [42] Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T -Cell (CAR -T) Therapy for Diffuse Large B -Cell Lymphoma
    Gupta, Shruti
    Seethapathy, Harish
    Strohbehn, Ian A.
    Frigault, Matthew J.
    O'Donnell, Elizabeth K.
    Jacobson, Caron A.
    Motwani, Shveta S.
    Parikh, Samir M.
    Curhan, Gary C.
    Reynolds, Kerry L.
    Leaf, David E.
    Sise, Meghan E.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2020, 76 (01) : 63 - 71
  • [43] Predictive and therapeutic biomarkers in chimeric antigen receptor T-cell therapy: A clinical perspective
    Mirzaei, Hamid Reza
    Mirzaei, Hamed
    Namdar, Afshin
    Rahmati, Majid
    Till, Brian G.
    Hadjati, Jamshid
    JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (05) : 5827 - 5841
  • [44] FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome
    Le, Robert Q.
    Li, Liang
    Yuan, Weishi
    Shord, Stacy S.
    Nie, Lei
    Habtemariam, Bahru A.
    Przepiorka, Donna
    Farrell, Ann T.
    Pazdur, Richard
    ONCOLOGIST, 2018, 23 (08) : 943 - 947
  • [45] Plasma exchange as an effective treatment for cytokine release syndrome following T cell receptor-engineered T cell immunotherapy: A case report
    Zheng, Xixi
    Zhang, Shuo
    Wu, Haiting
    Xia, Jinghua
    Zheng, Ke
    Wang, Ying
    Qin, Yan
    ONCOLOGY LETTERS, 2024, 28 (06)
  • [46] A distinct cytokine network distinguishes chimeric antigen receptor T cell (CAR-T)-associated hemophagocytic lymphohistiocytosis-like toxicity (carHLH) from severe cytokine release syndrome following CAR-T therapy
    Zu, Cheng
    Wu, Shenghao
    Zhang, Mingming
    Wei, Guoqing
    Xu, Huijun
    Cui, Jiazhen
    Chang, Alex H.
    Huang, He
    Hu, Yongxian
    CYTOTHERAPY, 2023, 25 (11) : 1167 - 1175
  • [47] Clinical trials for chimeric antigen receptor T-cell therapy: lessons learned and future directions
    Schroeder, Brett A.
    Jess, Jennifer
    Sankaran, Hari
    Shah, Nirali N.
    CURRENT OPINION IN HEMATOLOGY, 2022, 29 (04) : 225 - 232
  • [48] Chimeric Antigen Receptor (CAR) T-Cell Therapy in Hematologic Malignancies: Clinical Implications and Limitations
    Bluem, Philipp
    Kayser, Sabine
    CANCERS, 2024, 16 (08)
  • [49] Chimeric antigen receptor T-cell therapy: Foundational science and clinical knowledge for pharmacy practice
    Dushenkov, Anna
    Jungsuwadee, Paiboon
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (05) : 1217 - 1225
  • [50] Chimeric Antigen Receptor T-cell Therapy Current Status and Clinical Outcomes in Pediatric Hematologic Malignancies
    Talleur, Aimee C.
    Myers, Regina
    Annesley, Colleen
    Shalabi, Haneen
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2022, 36 (04) : 701 - 727